Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa

Current Opinion in Ophthalmology

Volumn 19, Issue 5, 2008, Pages 414-421

  Shome, Debraj ^a   Esmaeli, Bita ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti CD20 therapy; Benign lymphoid hyperplasia; Conjunctival lymphoma; Monoclonal antibody therapy; Orbital lymphoma; Radioimmunotherapy; Targeted therapy

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; STEROID; TOSITUMOMAB I 131; VINCRISTINE; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; CONJUNCTIVA; DRUG CONJUGATION; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; HISTOLOGY; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; OCULAR ADNEXAL LYMPHOMA; ORBIT TUMOR; ORBITAL BENIGN LYMPHOID HYPERPLASIA; ORBITAL LYMPHOMA; PANCYTOPENIA; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RELAPSE; REVIEW; TREATMENT RESPONSE; TUMOR CLASSIFICATION; CONJUNCTIVA TUMOR; EYELID TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANTIBODIES, MONOCLONAL; CONJUNCTIVAL NEOPLASMS; EYELID NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; ORBITAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY;

EID: 53049090850     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32830b1539     Document Type: Review

References (44)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours of haematopoietic and lymphoid tissues: pathology and genetics. Lyon: IARC Press; 2001.
2. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23:6524-6534.
3. Hartage P, Devesa SS, Franmeni JF. Hodgkin's and non-Hodgkin's lymphomas. In: Doll R, Franmeni JF, Muir C, editors. Trends in cancer incidence and mortality surveys. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1994. pp. 423-435.
4. Zinzani PL. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 2005; 32 (Suppl 1):S4-S10.
5. Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 2006; 108:1451-1460.
6. FitzpatrickPJ, MackoS. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 1984; 10:333-340.
7. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti WE, Sagerman RH, editors. Radiotherapy of intraocular and orbital tumors. Berlin, Germany: Springer-Verlag; 1993. pp. 205-216.
8. Feinstein AR, Krause AC. Ocular involvement in lymphomatous disease. Arch Ophthalmol 1952; 48:328-337.
9. Margo CE, Mulla ZD. Malignant tumors of the orbit: analysis of the Florida Cancer Registry. Ophthalmology 1998; 105:185-190.
10. Moslehi R, Devesa SS, Schairer C, et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst 2006; 98:936-939.
11. Shaye OS, Levine AM. Marginal zone lymphoma. J Natl Compr Canc Netw 2006; 4:311-318.
12. Guidoboni M, Ferreri AJM, Ponzoni M, et al. Infectious agents in mucosaassociated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma 2006; 6:289-300.
13. Hatef E, Roberts D, McLaughlin P, et al. Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol 2007; 125:1663-1667.
14. Bardenstein DS. Ocular adnexal lymphoma: classification, clinical disease, and molecular biology. Ophthalmol Clin North Am 2005; 18:187-197.
15. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmology 1998; 105:1430-1441.
16. Knowles DM, Jakobiec FA, McNally L, et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 1990; 21:959-973.
17. McKelvie PA, McNab A, Francis IC, et al. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol 2001; 29:387-393.
18. Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59:139-144.
19. Shields CL, Shields JA, Carvahlo C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology 2001; 108:979-984.
20. Gayed I, Eskandari MF, McLaughlin P, et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging 2007; 110:809-815.
21. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57:1382-1391.
22. BolekTW, Moyses HM, Marcus RB Jr, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999; 44:31-36.
23. BhatiaS, Paulino AC, Buatti JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54:818-823.
24. Winter JN. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. Curr Opin Hematol 2007; 14:360-368.
25. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66:791-820.
26. Plosker GL, Figgitt DP. Rituximab: a review of its use in nonhodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-843.
27. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo) 2005; 46:241-248.
28. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-3732.
29. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systemic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714.
30. Esmaeli B, Murray JL, Ahmadi MA, et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 2002; 120:1225-1227.
31. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 2004; 20:103-106.
32. Zinzani PL, Alinari L, Stefoni V, et al. Rituximab in primary conjunctival lymphoma. Leuk Res 2005; 29:107-108.
33. Ferreri AJ, Ponzoni M, Matinelli G, et al. Rituximab in patients with mucosalassociated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90:1578-1579.
34. Rigacci L, Nassi L, Puccioni M, et al. Rituximab and chlorambucil as first line treatment for low-grade ocular adnexal lymphomas. Ann Hematol 2007; 86:565-568.
35. Grillo-Lopez AJ, Dallaire BK, Mc Clure A, et al. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2001; 2:301-311.
36. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human B-lymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1982; 41:411-420.
37. Safwat A. The role of low-dose total body irradiation in treatment of nonHodgkin's lymphoma: a new look at an old method. Radiother Oncol 2000; 56:1-8.
38. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003; 30 (Suppl 4):10-21.
39. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63:1424-1433.
40. Santos ES, Kharfan-Dabaja MA, Ayala E, Raez LE. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:2453-2476.
41. Chapuy B, Hohloch K, Trumper L. Yttrium 90 ibritumomabtiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma? Biotechnol J 2007; 2:1435-1443.
42. 131I-tositumomab in clinical practice. J Nucl Med 2007; 48:1 767-1776.
43. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23:712-719.
44. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.